Moxifloxacin Aurobindo (Moxifloxacin Hydrochloride)

Moxifloxacin is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory and other systems.

• Community‑acquired pneumonia: improves clinical cure rates and reduces bacterial load in adult patients.
• Acute bacterial sinusitis: alleviates sinus inflammation and eradicates causative pathogens.
• Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents further lung damage.
• Skin and skin‑structure infections: resolves cellulitis and related soft‑tissue infections.
• Complicated intra‑abdominal infections: provides broad coverage against mixed aerobic and anaerobic organisms.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA breaks, leading to halted bacterial DNA synthesis and cell death. This dual‑target action confers potent bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertiginous sensation.
• Abdominal pain: cramping or discomfort.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: risk of cardiac arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema.
• Clostridioides difficile infection: colitis due to gut flora disruption.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Photosensitivity: heightened skin reaction to sunlight.

When prescribing Moxifloxacin, clinicians should consider several safety precautions to minimise risk.

• Assess renal and hepatic function: adjust monitoring in patients with impairment.
• Avoid in patients with known hypersensitivity to fluoroquinolones.
• Use caution in individuals with a history of tendon disorders.
• Monitor cardiac rhythm in patients taking other QT‑prolonging agents.
• Avoid concomitant use with antacids containing aluminum or magnesium: may reduce absorption.
• Store at room temperature (below 25 °C): keep in original packaging, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with other fluoroquinolones: increased risk of tendon toxicity.
• Co‑administration with systemic corticosteroids: heightened tendon rupture risk.
• Combination with drugs that prolong QT interval (e.g., quinidine, macrolides): risk of cardiac arrhythmia.
• Use with antacids containing aluminum or magnesium: markedly reduces absorption.
• Interaction with warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase CNS stimulation.
• Theophylline: potential for elevated plasma levels.
• Cyclosporine: possible increased concentrations.
• Oral contraceptives: reduced effectiveness reported.
• Diabetes medications: monitor blood glucose as fluoroquinolones can affect glycemic control.